Charles River
A day in the life of… Katy McQuate, Charles River
A day in the life of… Monique Bodil van Niel, Charles River
Ask the Expert on Microsampling ¦Tim Sangster (Charles River)
Interview with Kelly Colletti (Charles River) on Charles River’s global clinical working group
Charles River announces acquisition of Cellero
Charles River Laboratories to acquire Citoxlab
Charles River to secure MPI Research
Partnership announced between Charles River Laboratories and InSphero AG
Summary:
Stakeholders in academia, industry, and CROs are committed to building a complete platform to develop therapies for rare diseases, and they are using their combined expertise and resources to get there. “There is a continual push amongst people who work in rare diseases to bring [treatments] forward quicker,” notes Dr Martin Mackay, PhD, the former Head of Research and Development at Alexion Pharmaceuticals.
The unique capabilities of CROs, like Charles River, allow the design of customized rare disease studies using pre-existing methods, considerably increasing the efficiency and effectiveness of novel therapeutic development.
Thousands of rare diseases still lack novel therapies. But the creation of a robust collaborative ecosystem will ultimately facilitate efficient drug development for the patients who desperately need it.
Click here to see the video!
Watch this Panel discussion on new technology integration in bioanalytical workflows
With a commitment to scientific excellence, Charles River provides industry-leading GCP and GLP laboratory services to support our clients’ drug development, from discovery to the clinic. Whether clients need stand-alone solutions or a package tailored to meet their needs, we apply our in-depth knowledge of biomarkers, traditional NCEs, proteins, and large molecules to optimize their discovery and development programs to accelerate the journey to market. Our focus on partnership ensures our clients receive the very best in personalized service and support. From compound screening, rapid custom PK and immunogenicity assay development, validation and sample analysis to on-time reporting, we can support our clients’ research and protect their investment, every step of the way.
The Laboratory Sciences team at Charles River balances scientific integrity, cost-effectiveness and regulatory compliance within the most stringent of time frames to deliver comprehensive support throughout the entire drug discovery and development process. Our global capabilities ensure that you have the resources necessary to handle all of your laboratory support needs, or simply to supplement your in-house capabilities.
We believe in remaining at the forefront of laboratory technology and have made significant investments in highly trained chemists, facilities and instrumentation to produce rapid and reliable data.
Areas of expertise include:
• Bioanalysis
• Compound screening and lead optimization
• Drug metabolism and pharmacokinetics (DMPK)
• Clinical sample kits
• Immunology
• Molecular biology
• Biomarker assay development, validation and sample analysis
• Formulation development, pharmacy and analytical chemistry
• Genetic toxicology
• In vitro services
Website: http://www.criver.com
Email: [email protected]
Telephone: 1-877-274-8371
Address:
Corporate Head Quarters:
251 Ballardvale Street
Wilmington, MA 01887
US
1-877-274-8371
Global Facilities located in the United States, Canada, UK, and Europe